GlassScriptPhysician profile
Meredith L Itz
NPI 1265735567
$2,133.25
in general payments reported to CMS, 2019-2025
22 companies · $727 in 2025
The $727 reported for 2025 was more than what 79% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.72 · 2022: $141 · 2023: $579 · 2024: $619 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $474.85 | 2021-2025 | |
| Amgen INC. | $291.43 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $267.54 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $170.71 | 2024-2025 | Verquvo, Winrevair, Capvaxive |
| Janssen Pharmaceuticals, INC | $136.68 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $109.93 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $103.92 | 2023-2025 | Brilinta, Farxiga |
| Scpharmaceuticals INC. | $80.61 | 2023-2025 | |
| Esperion Therapeutics, INC. | $73.14 | 2023-2025 | Nexletol |
| Abbott Laboratories | $68.13 | 2023-2024 | Jot Dx, Cardiomems |
| Lilly USA, LLC | $43.90 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.02 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $36.63 | 2022 | |
| Inspire Medical Systems, INC. | $35.58 | 2025 | Inspire |
| Melinta Therapeutics, LLC | $32.84 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29.82 | 2025 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $29.25 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $27.06 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $23.19 | 2024 | Opsumit, Uptravi |
| Avadel Cns Pharmaceuticals, LLC | $20.03 | 2025 | Lumryz |
| Atricure, INC. | $19.85 | 2023 | |
| Amarin Pharma, INC. | $16.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Itz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.